Metabolic Reprogramming from Glycolysis to Fatty Acid Uptake and beta-Oxidation in Platinum-Resistant Cancer Cells
J. Li, Y. Tan, G. Zhao, K.-C. Huang, H. Cardenas, D. Matei, J.-X. Cheng
Abstract
Increased aerobic glycolysis is widely considered as a hallmark of cancer. Yet, cancer cell metabolic reprograming during development of therapeutic resistance is under-studied. Here, through high-throughput stimulated Raman scattering imaging and single cell analysis, we found that cisplatin-resistant cells exhibit increased uptake of exogenous fatty acids, accompanied with decreased glucose uptake and de novo lipogenesis, indicating a reprogramming from glucose and glycolysis dependent to fatty acid uptake and beta-oxidation dependent anabolic and energy metabolism. A metabolic index incorporating measurements of glucose derived anabolism and fatty acid uptake correlates linearly to the level of resistance to cisplatin in ovarian cancer cell lines and in primary cells isolated from ovarian cancer patients. Mechanistically, the increased fatty acid uptake facilitates cancer cell survival under cisplatin-induced oxidative stress by enhancing energy production through beta-oxidation. Consequently, blocking fatty acid beta-oxidation by a small molecule inhibitor in combination with cisplatin or carboplatin synergistically suppressed ovarian cancer proliferation in vitro and growth of patient-derived xenograft in vivo. Collectively, these findings support a new way for rapid detection of cisplatin-resistance at single cell level and a new strategy for treatment of cisplatin-resistant tumors.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Platinum-Induced Mitochondrial OXPHOS Contributes to Cancer Stem Cell Enrichment in Ovarian Cancer
S. Sriramkumar, R. Sood, … H. M. OHagan·Journal of Translational MedicinePeer-reviewed·May 31, 2022
- Restoring p53 Function and Silencing REV3L Suppresses the Cancerous Metabolic Phenotype in Cisplatin Treated Human Non-Small Lung Carcinoma Cells
L. Kong, M. M. Murata, M. A. Digman·bioRxiv·Oct 10, 2017
- Glutamine-addiction in cisplatin resistant cancer cells is mediated by SLC7A11 and can be targeted with asparaginase therapy
J.S. Wang, Robert Strauss, … Sean G. Rudd·bioRxiv·Jul 19, 2024
- Therapy-induced lipid uptake and remodeling underpin ferroptosis hypersensitivity in prostate cancer
K. D. Tousignant, A. Rockstroh, … M. C. Sadowski·bioRxiv·Jan 8, 2020
- Metabolic plasticity increases evolvability and drives persistence to PARP inhibitor in ovarian cancer
Adriana Del Pino Herrera, Joon-Hyun Song, … Meghan C. Ferrall-Fairbanks·bioRxiv·Oct 8, 2025
- Glutaminase as a metabolic target of choice to counter acquired resistance to Palbociclib by colorectal cancer cells
Míriam Tarrado‐Castellarnau, Carles Foguet, … Marta Cascante·OncogenePeer-reviewed·Jul 22, 2025